Avanos Medical
- Home ›
- US ›
- Healthcare
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life worldwide. The last earnings update was 43 days ago. More info.
Add to Portfolio Compare Print
AVNS Share Price and Events
7 Day Returns
1 Year Returns
AVNS Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Avanos Medical (AVNS) | 3.5% | 4.2% | 4% | -26.7% | 35.2% | - |
| US Medical Equipment | 0% | 6.1% | 1.6% | 12.8% | 61.8% | 95.3% |
| US Market | 0.1% | 0.6% | 0.9% | 1.2% | 36.7% | 37.9% |
1 Year Return vs Industry and Market
- AVNS underperformed the Medical Equipment industry which returned 12.8% over the past year.
- AVNS underperformed the Market in United States of America which returned 1.2% over the past year.
Value
Is Avanos Medical undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Avanos Medical
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Avanos Medical.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 7 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.85 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.85 (1 + (1- 21%) (15.07%)) |
0.968 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.97 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.968 * 5.96%) |
8.5% |
Discounted Cash Flow Calculation for NYSE:AVNS using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Avanos Medical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.5%) |
|
|---|---|---|---|
| 2019 | 23.00 | Analyst x1 | 21.20 |
| 2020 | 56.00 | Analyst x1 | 47.57 |
| 2021 | 103.00 | Analyst x1 | 80.65 |
| 2022 | 107.00 | Analyst x1 | 77.22 |
| 2023 | 119.00 | Analyst x1 | 79.15 |
| 2024 | 128.83 | Est @ 8.26% | 78.98 |
| 2025 | 137.33 | Est @ 6.6% | 77.59 |
| 2026 | 144.80 | Est @ 5.44% | 75.41 |
| 2027 | 151.49 | Est @ 4.63% | 72.72 |
| 2028 | 157.64 | Est @ 4.06% | 69.74 |
| Present value of next 10 years cash flows | $680.22 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $157.64 × (1 + 2.73%) ÷ (8.5% – 2.73%) |
$2,808.04 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $2,808.04 ÷ (1 + 8.5%)10 |
$1,242.28 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $680.22 + $1,242.28 |
$1,922.50 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $1,922.50 / 47.50 |
$40.47 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $40.47 |
| Current discount | Discount to share price of
$44.32
= -1 x ($44.32 - $40.47) / $40.47 |
-9.5% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Avanos Medical is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Avanos Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Avanos Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-0.37 |
| NYSE:AVNS Share Price ** | NYSE (2019-06-18) in USD | $44.32 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 64 Publicly-Listed Medical Equipment Companies | 40.71x |
| United States of America Market PE Ratio | Median Figure of 3,092 Publicly-Listed Companies | 17.63x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Avanos Medical.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NYSE:AVNS Share Price ÷ EPS (both in USD) = 44.32 ÷ -0.37 |
-119.92x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Avanos Medical is loss making, we can't compare its value to the US Medical Equipment industry average.
- Avanos Medical is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Avanos Medical's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -119.92x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
88.5%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 55 Publicly-Listed Medical Equipment Companies | 2.27x |
| United States of America Market PEG Ratio | Median Figure of 2,126 Publicly-Listed Companies | 1.53x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Avanos Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Avanos Medical's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $27.04 |
| NYSE:AVNS Share Price * | NYSE (2019-06-18) in USD | $44.32 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 183 Publicly-Listed Medical Equipment Companies | 4.39x |
| United States of America Market PB Ratio | Median Figure of 5,244 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NYSE:AVNS Share Price ÷ Book Value per Share (both in USD) = 44.32 ÷ 27.04 |
1.64x |
* Primary Listing of Avanos Medical.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Avanos Medical is good value based on assets compared to the US Medical Equipment industry average.
Value checks
We assess Avanos Medical's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Avanos Medical has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Avanos Medical's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Avanos Medical's earnings growth is expected to exceed the United States of America market average.
- Avanos Medical's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NYSE:AVNS Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 88.5% |
| NYSE:AVNS Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 6.2% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 22% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.9% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | ||||
| 2022-12-31 | 833 | 2 | ||
| 2021-12-31 | 787 | 133 | 87 | 5 |
| 2020-12-31 | 742 | 105 | 68 | 6 |
| 2019-12-31 | 695 | 36 | -33 | 7 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 660 | -195 | -18 |
| 2018-12-31 | 652 | -146 | -9 |
| 2018-09-30 | 649 | -74 | -1 |
| 2018-06-30 | 634 | 17 | -16 |
| 2018-03-31 | 622 | 134 | -29 |
| 2017-12-31 | 612 | 144 | -32 |
| 2017-09-30 | -171 | 125 | -150 |
| 2017-06-30 | 76 | 152 | -130 |
| 2017-03-31 | 327 | 183 | -112 |
| 2016-12-31 | 566 | 189 | -83 |
| 2016-09-30 | 1,584 | 167 | 44 |
| 2016-06-30 | 1,576 | 136 | -435 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Avanos Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | ||||
| 2022-12-31 | ||||
| 2021-12-31 | 1.88 | 2.21 | 1.51 | 3.00 |
| 2020-12-31 | 1.42 | 1.74 | 1.09 | 4.00 |
| 2019-12-31 | -0.58 | -0.46 | -0.69 | 2.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -0.37 |
| 2018-12-31 | -0.18 |
| 2018-09-30 | -0.03 |
| 2018-06-30 | -0.34 |
| 2018-03-31 | -0.61 |
| 2017-12-31 | -0.69 |
| 2017-09-30 | -3.21 |
| 2017-06-30 | -2.79 |
| 2017-03-31 | -2.41 |
| 2016-12-31 | -1.79 |
| 2016-09-30 | 0.95 |
| 2016-06-30 | -9.34 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Avanos Medical's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Avanos Medical has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Avanos Medical performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Avanos Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Avanos Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Avanos Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Avanos Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 660.10 | -17.50 | 342.70 | 42.10 |
| 2018-12-31 | 652.30 | -8.50 | 324.70 | 41.80 |
| 2018-09-30 | 648.70 | -1.40 | 315.80 | 43.30 |
| 2018-06-30 | 634.10 | -15.80 | 313.00 | 42.40 |
| 2018-03-31 | 622.30 | -28.50 | 318.30 | 40.80 |
| 2017-12-31 | 611.60 | -32.10 | 316.70 | 38.20 |
| 2017-09-30 | -170.80 | -149.60 | 289.50 | 35.40 |
| 2017-06-30 | 76.20 | -130.30 | 311.40 | 36.70 |
| 2017-03-31 | 327.10 | -112.40 | 338.20 | 37.00 |
| 2016-12-31 | 566.20 | -83.30 | 346.20 | 38.40 |
| 2016-09-30 | 1,583.70 | 44.30 | 421.30 | 16.90 |
| 2016-06-30 | 1,575.70 | -435.30 | 418.20 | 16.20 |
| 2016-03-31 | 1,565.00 | -433.80 | 416.10 | 13.00 |
| 2015-12-31 | 509.00 | -101.20 | 349.70 | 27.60 |
| 2015-09-30 | 1,612.40 | -443.20 | 443.60 | 13.00 |
| 2015-06-30 | 1,631.40 | 19.90 | 457.70 | 11.30 |
| 2015-03-31 | 1,655.60 | 7.40 | 460.20 | 14.30 |
| 2014-12-31 | 1,672.10 | 27.10 | 441.50 | 16.60 |
| 2014-09-30 | 1,664.00 | 69.30 | 382.60 | 39.80 |
| 2014-06-30 | 1,675.00 | 124.60 | 353.80 | 40.20 |
| 2014-03-31 | 1,677.40 | 167.70 | 337.40 | 38.70 |
| 2013-12-31 | 1,677.50 | 154.60 | 368.40 | 20.90 |
| 2012-12-31 | 1,684.00 | 152.60 | 343.00 | 33.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Avanos Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Avanos Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Avanos Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Avanos Medical's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Avanos Medical has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Avanos Medical's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Avanos Medical's finances.
The net worth of a company is the difference between its assets and liabilities.
- Avanos Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Avanos Medical's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Avanos Medical Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 1,280.10 | 317.30 | 348.30 |
| 2018-12-31 | 1,297.20 | 247.70 | 384.50 |
| 2018-09-30 | 1,300.20 | 247.60 | 411.80 |
| 2018-06-30 | 1,286.60 | 247.40 | 479.60 |
| 2018-03-31 | 1,251.80 | 542.00 | 203.10 |
| 2017-12-31 | 1,215.40 | 580.90 | 219.70 |
| 2017-09-30 | 1,180.70 | 580.40 | 166.10 |
| 2017-06-30 | 1,156.80 | 579.90 | 154.80 |
| 2017-03-31 | 1,130.90 | 579.40 | 143.10 |
| 2016-12-31 | 1,102.50 | 579.00 | 113.70 |
| 2016-09-30 | 1,101.50 | 589.40 | 86.70 |
| 2016-06-30 | 1,089.50 | 624.00 | 79.20 |
| 2016-03-31 | 1,079.80 | 578.50 | 165.10 |
| 2015-12-31 | 1,055.30 | 578.10 | 129.50 |
| 2015-09-30 | 1,041.00 | 585.90 | 112.50 |
| 2015-06-30 | 1,521.80 | 585.80 | 114.30 |
| 2015-03-31 | 1,511.80 | 635.30 | 166.20 |
| 2014-12-31 | 1,491.20 | 626.50 | 149.00 |
| 2014-09-30 | 2,079.00 | 10.90 | 58.40 |
| 2014-06-30 | 2,077.30 | 10.40 | 48.50 |
| 2014-03-31 | 2,103.50 | 9.40 | 35.80 |
| 2013-12-31 | 2,079.10 | 11.90 | 44.10 |
| 2012-12-31 | 2,055.70 | 75.90 | 47.90 |
- Avanos Medical's level of debt (19.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0.4% vs 19.4% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Avanos Medical has sufficient cash runway for 1.4 years based on current free cash flow.
- Avanos Medical has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 89.7% each year.
Financial health checks
We assess Avanos Medical's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Avanos Medical has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Avanos Medical's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Avanos Medical
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Avanos Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Avanos Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.2% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Avanos Medical has not reported any payouts.
- Unable to verify if Avanos Medical's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Avanos Medical's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Avanos Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Avanos Medical has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $7,157,269 |
| AGE | 52 |
| TENURE AS CEO | 2 years |
CEO Bio
Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Halyard Health, Inc. since June 26, 2017. Mr. Woody served as the Chief Executive Officer and President of Acelity Holdings, Inc. since August 2015 until April 2017. Mr. Woody served as an Interim Chief Executive Officer of LifeCell Corporation since April 12, 2013 until August 2015. He served as the Chief Executive Officer and President of Kinetic Concepts, Inc. and Systagenix Wound Management Limited from September 2013 to August 2015. Mr. Woody served as the Chief Executive Officer of Acelity L.P. Inc. since January 2012 until April 2017 and served as its President. Mr. Woody served as Global President of Vascular Therapies for Covidien plc. He served as Global President of Active Healing Solutions(Tm) at KCI since November 2011. Mr. Woody served in leadership roles at KCI and LifeCell from November 2011 to September 2013, having been promoted to President and Chief Executive Officer of KCI in January 2012. He served as the President of Advanced Wound Management at Smith & Nephew, Inc. Mr. Woody served as Vice President and General Manager of Clinical Therapies Group (Division) of Smith & Nephew Endoscopy, Inc. since March 2004. He served for Alliance Imaging, Inc., Acuson and General Electric Medical Systems (GE Medical Systems) before joining Smith & Nephew in 2003. He has more than 20 years of experience in the healthcare sector. He has been a Director of Chiron Holdings GP, Inc., the general partner of Chiron Guernsey Holdings L.P. Inc., which is the parent of Centaur Guernsey L.P. Inc. since April 3, 2012. He served as a Director at Acelity Holdings, Inc. since August 2015 until April 2017. He served as a Director of Advanced Wound Medical Technology Association (AdvaMed). Mr. Woody served as a Director of Acelity L.P. Inc. since April 3, 2012 until April 2017. He served as a Director of Kinetic Concepts, Inc. He served as a Director of Systagenix Wound Management Ltd. since July 26, 2011. He is chair of the Wound Healing and Tissue Regeneration Sector.
CEO Compensation
- Joe's compensation has increased whilst company is loss making.
- Joe's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Avanos Medical management team in years:
- The average tenure for the Avanos Medical management team is less than 2 years, this suggests a new team.
Management Team
Joe Woody
CEO & Director
$7M
52
2 yrs
John Wesley
Senior Vice President of Legal & Government Relations
$1M
59
John Tushar
President of Global Franchises
$1M
56
1.3 yrs
Arjun Sarker
Senior Vice President of International
$1M
52
1.2 yrs
Warren MacHan
Senior VP of Business Strategy & Interim CFO
52
0.1 yrs
Renato Negro
VP, Controller & Chief Accounting Officer
Dave Crawford
VP of FP&A and Investor Relations and Treasurer
Rhonda Gibby
Senior VP & Chief Human Resources Officer
$1M
50
4.7 yrs
Lee Burnes
Senior Vice President of Global R&D
Dave Ball
Senior Vice President of Global Supply Chain & Procurement
59
0.5 yrs
Board of Directors Tenure
Average tenure and age of the Avanos Medical board of directors in years:
- The tenure for the Avanos Medical board of directors is about average.
Board of Directors
Ron Dollens
Chairman of the Board
$345K
71
1.8 yrs
Joe Woody
CEO & Director
$7M
52
2 yrs
Heidi Fields
Independent Director
$245K
63
4.7 yrs
Julie Shimer
Independent Director
$245K
65
4.7 yrs
Gary Blackford
Independent Director
$245K
61
4.7 yrs
Bill Hawkins
Independent Director
$245K
64
3.5 yrs
John Byrnes
Independent Director
$230K
59
4.7 yrs
Patrick O'Leary
Independent Director
$230K
60
4.7 yrs
Maria Sainz
Independent Director
$230K
52
4.3 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Avanos Medical insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 03. Jun 19 | Buy | Joseph Woody | Individual | 30. May 19 | 30. May 19 | 3,500 | $39.95 | $139,825 | ||
| 29. Nov 18 | Buy | Joseph Woody | Individual | 28. Nov 18 | 28. Nov 18 | 3,500 | $43.35 | $151,725 | ||
| 28. Nov 18 | Buy | Steven Voskuil | Individual | 27. Nov 18 | 27. Nov 18 | 2,000 | $43.74 | $87,470 | ||
| 20. Nov 18 | Buy | John Wesley | Individual | 19. Nov 18 | 19. Nov 18 | 1,000 | $47.48 | $47,480 | ||
Management checks
We assess Avanos Medical's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Avanos Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Should You Think About Buying Avanos Medical, Inc. (NYSE:AVNS) Now?
It’s trading around 8.15% above my intrinsic value, which means if you buy Avanos Medical today, you’d be paying a relatively reasonable price for it. … Given that Avanos Medical’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. … However, the optimistic prospect is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.
Simply Wall St - – Full articleMarket Sentiment Around Loss-Making Avanos Medical, Inc. (NYSE:AVNS)
I’ve put together a brief outline of industry analyst expectations for AVNS, its year of breakeven and its implied growth rate. … View our latest analysis for Avanos Medical According to the 7 industry analysts covering AVNS, the consensus is breakeven is near. … NYSE:AVNS Past and Future Earnings, May 27th 2019 Given this is a high-level overview, I won’t go into details of AVNS’s upcoming projects, but, take into account that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.
Simply Wall St - – Full articleA Look At The Fair Value Of Avanos Medical, Inc. (NYSE:AVNS)
by taking the foreast future cash flows of the company and discounting them back to today's value. … I will use the Discounted Cash Flow (DCF) model! … If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleNeed To Know: Avanos Medical, Inc. (NYSE:AVNS) Insiders Have Been Buying Shares
So we'll take a look at whether insiders have been buying or selling shares in Avanos Medical, Inc. … Avanos Medical Insider Transactions Over The Last Year. … While Avanos Medical insiders bought shares last year, they didn't sell
Simply Wall St - – Full articleWhy Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching
As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock? … However, could the stock still be trading at a relatively cheap price. … Today I will analyse the most recent data on Avanos Medical’s outlook and valuation to see if the opportunity still exists
Simply Wall St - – Full articleIs Avanos Medical, Inc. (NYSE:AVNS) As Strong As Its Balance Sheet Indicates?
Mid-caps stocks, like Avanos Medical, Inc. … Today we will look at AVNS’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … View our latest analysis for Avanos Medical
Simply Wall St - – Full articleAvanos Medical, Inc. (NYSE:AVNS): Time For A Financial Health Check
(NYSE:AVNS) is a small-cap stock with a market capitalization of US$1.9b. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes
Simply Wall St - – Full articleHow Do Avanos Medical, Inc.’s (NYSE:AVNS) Returns On Capital Compare To Peers?
In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … What is Return On Capital Employed (ROCE)? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.
Simply Wall St - – Full articleAt US$47.02, Is Avanos Medical Inc (NYSE:AVNS) Worth Looking At Closely?
Avanos Medical Inc (NYSE:AVNS), which is in the medical equipment business, and is based in United States,. … A question to answer is whether Avanos Medical's current trading price of $47.02 reflective of the actual value of the? … Let’s take a look at Avanos Medical’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change
Simply Wall St - – Full articleWho Owns Most Of Avanos Medical Inc (NYSE:AVNS)?
We also tend to see lower insider ownership in companies that were previously publicly owned. … Avanos Medical has a market capitalization of US$3.0b, so we would expect some institutional investors to have noticed the stock. … institutional investors have bought into the company.
Simply Wall St - – Full articleCompany Info
Description
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. The company also offers Game Read, a product for pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries; GRPro 2.1, a cold and compression therapy system; Med4Elite, a multi-modality therapy unit; ATX Wraps; and various product accessories. In addition, it sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and GAME READY brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Details
| Name: | Avanos Medical, Inc. |
| AVNS | |
| Exchange: | NYSE |
| Founded: | 2014 |
| $2,105,407,417 | |
| 47,504,680 | |
| Website: | http://avanos.com |
| Address: |
Avanos Medical, Inc. 5405 Windward Parkway, Suite 100 South, Alpharetta, Georgia, 30004, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NYSE | AVNS | Common Stock | New York Stock Exchange | US | USD | 22. Oct 2014 | |
| DB | 8HH | Common Stock | Deutsche Boerse AG | DE | EUR | 22. Oct 2014 |
Number of employees
Current staff
Industry
| Health Care Supplies | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/19 00:46 |
| End of day share price update: | 2019/06/18 00:00 |
| Last estimates confirmation: | 2019/05/23 |
| Last earnings filing: | 2019/05/07 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
